Recombinant modified vaccinia ankara (MVA) vaccinia virus containing restructured insertion sites

Patent metadata

Field	Value
Publication number	US-9879231-B2
Application number	US-201514837382-A
Country	US
Kind code	B2
Filing date	Aug 27, 2015
Priority date	Oct 16, 2009
Publication date	Jan 30, 2018
Grant date	Jan 30, 2018

Abstract

The present invention relates to recombinant modified vaccinia Ankara (MVA) virus containing restructured sites useful for the integration of heterologous nucleic acid sequences into an intergenic region (IGR) of the virus genome, where the IGR is located between two adjacent, essential open reading frames (ORFs) of the vaccinia virus genome, wherein the adjacent essential ORFs are non-adjacent in a parental MVA virus used to construct the recombinant MVA virus, and to related nucleic acid constructs useful for inserting heterologous DNA into the genome of a vaccinia virus, and further to the use of the disclosed viruses as a medicine or vaccine.

First claim

What is claimed is:

1. An isolated nucleic acid construct comprising:
(a) a first nucleic acid sequence derived from, or homologous to, a first essential ORF from a poxvirus genome; and
(b) a second nucleic acid sequence derived from, or homologous to, a second essential ORF from a poxvirus genome;
wherein the first and second essential poxvirus ORFs are separated by at least one non-essential ORF in the parental poxvirus genome, and wherein the first and second nucleic acid sequences are adjacent to each other in the isolated nucleic acid construct.

2. The isolated nucleic acid sequence of claim 1 , wherein the first nucleic acid sequence comprises at least 20 contiguous nucleotides from the first essential ORF, and wherein the second nucleic acid sequence comprises at least 20 contiguous nucleotides from the second essential ORF.

3. The isolated nucleic acid construct of claim 1 , wherein the first nucleic acid sequence comprises an at least 100 contiguous polynucleotide region that is at least 75% identical to an at least 100 contiguous polynucleotide region in the first essential ORF, and wherein the second nucleic acid sequence comprises an at least 100 contiguous polynucleotide region that is at least 75% identical to an at least 100 contiguous polynucleotide region in the second essential ORF.

4. The isolated nucleic acid construct of claim 1 , wherein the first essential ORF is selected from the group consisting of A11R, A12L, A50R, B1R, F10, F12, F13L, F15L, F17R, G1L, H2R, H3L, E1L, E4L, E6L, E8L, E10L, I1L, I3L, I5L, I8R, J1R, J3R, J4R, J5L, D7L, D9L, A24R, and A28R.

5. The isolated nucleic acid construct of claim 1 , wherein the second essential ORF is selected from the group consisting of A11R, A12L, A50R, B1R, F10, F12, F13L, F15L, F17R, G1L, H2R, H3L, E1L, E4L, E6L, E8L, E10L, I1L, I3L, I5L, I8R, J1R, J3R, J4R, J5L, D7L, D9L, A24R, and A28R.

6. The isolated nucleic acid construct of claim 1 , wherein the first essential ORF is A50R and the second essential ORF is B1R.

7. The isolated nucleic acid construct of claim 1 , wherein adjacent ends of the first and second nucleic acid sequences are separated by a third nucleic acid sequence comprising at least one nucleotide sequence selected from the group consisting of (a) an intergenic region, and (b) a restriction enzyme recognition site.

8. The isolated nucleic acid construct of claim 1 , wherein adjacent ends of the first and second nucleic acid sequences are separated by a heterologous nucleic acid sequence.

9. The isolated nucleic acid construct of claim 8 , wherein the heterologous nucleic sequence comprises at least one coding sequence under the transcriptional control of a transcriptional control element.

10. The isolated nucleic acid construct of claim 1 , wherein the poxvirus genome is from a poxvirus in the subfamily Chordopoxvirinae.

11. The isolated nucleic acid construct of claim 1 , wherein the poxvirus genome is from a poxvirus in the genus Orthopoxvirus.

12. A method for producing a stable, recombinant poxvirus, the method comprising:
(a) transfecting a cell with a nucleic acid construct comprising:
i. a first nucleic acid sequence derived from, or homologous to, a first essential ORF from a poxvirus genome; and,
ii. a second nucleic acid sequence derived from, or homologous to, a second essential ORF from a poxvirus genome;

wherein the first and second essential poxvirus ORFs are separated by at least one non-essential ORF in the parental poxvirus genome, and wherein the first and second nucleic acid sequences are adjacent to each other in the isolated nucleic acid construct;
(b) infecting the transfected cell with a poxvirus;
(c) culturing the infected cell under conditions suitable to allow homologous recombination between the nucleic acid construct and the poxvirus genome.

13. The method of claim 12 , wherein the first nucleic acid sequence comprises at least 20 contiguous nucleotides from the first essential ORF, and wherein the second nucleic acid sequence comprises at least 20 contiguous nucleotides from the second essential ORF.

14. The method of claim 12 , wherein the first nucleic acid sequence comprises an at least 100 contiguous polynucleotide region that is at least 75% identical to an at least 100 contiguous polynucleotide region in the first essential ORF, and wherein the second nucleic acid sequence comprises an at least 100 contiguous polynucleotide region that is at least 75% identical to an at least 100 contiguous polynucleotide region in the second essential ORF.

15. The method of claim 12 , wherein the first essential ORF is selected from the group consisting of A11R, A12L, A50R, B1R, F10, F12, F13L, F15L, F17R, G1L, H2R, H3L, E1L, E4L, E6L, E8L, E10L, I1L, I3L, I5L, I8R, J1R, J3R, J4R, J5L, D7L, D9L, A24R, and A28R.

16. The method of claim 12 , wherein the second essential ORF is selected from the group consisting of A11R, A12L, A50R, B1R, F10, F12, F13L, F15L, F17R, G1L, H2R, H3L, E1L, E4L, E6L, E8L, E10L, I1L, I3L, I5L, I8R, J1R, J3R, J4R, J5L, D7L, D9L, A24R, and A28R.

17. The method of claim 12 , wherein the first essential ORF is A50R and the second essential ORF is B1R.

18. The method of claim 12 , wherein adjacent ends of the first and second nucleic acid sequences are separated by a third nucleic acid sequence comprising at least one nucleotide sequence selected from the group consisting of (a) an intergenic region, and (b) a restriction enzyme recognition site.

19. The method of claim 12 , wherein adjacent ends of the first and second nucleic acid sequences are separated by a heterologous nucleic acid sequence.

20. The method of claim 19 , wherein the heterologous nucleic sequence comprises at least one coding sequence under the transcriptional control of a transcriptional control element.

Assignees

• Us Health
• Us Health

Inventors

• Moss Bernard
• Wyatt Linda S
• Earl Patricia L

Classifications

• A61P37/04

  Immunostimulants · CPC title

• A61P31/18

  for HIV · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P31/14

  for RNA viruses · CPC title

• C12N2710/24152

  relating to complementing cells and packaging systems for producing virus or viral particles · CPC title